From Yahoo Finance: 2025-04-24 16:09:00

Gilead Sciences reported a first-quarter profit, with flat revenue of $6.7 billion as higher HIV and liver disease drug sales offset lower cancer drug revenue. Shares fell 3% in after-hours trading. Adjusted earnings per share were $1.81, beating estimates, and the FDA is expected to decide on lenacapavir HIV prevention drug by June 19.

Sales of HIV drug Biktarvy rose 7% to $3.15 billion, liver disease drugs up 3% to $758 million. Cancer drug Trodelvy sales fell 5% to $293 million, cell therapy sales down 3% to $464 million due to pricing and competition. Gilead expects flat HIV revenue in 2025 due to Medicare changes.

Gilead’s research and development expenses were $1.4 billion, down from $1.5 billion, while sales and administrative costs dropped to $1.3 billion from $1.4 billion. The company expects adjusted earnings of $7.70 to $8.10 per share for the full year on product sales of $28.2 billion to $28.6 billion.



Read more at Yahoo Finance: Gilead posts profit, says HIV prevention drug on track for mid-June